Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Hypnion said that the primary and secondary endpoints were met in an initial phase II trial evaluating HY10275 in adults with insomnia.
Subscribe to our email newsletter
In the study HY10275 demonstrated statistically significant improvements in Wake After Sleep Onset (WASO) in both 1mg and 3mg doses studied. WASO decreased in a dose dependent manner by 62 minutes for 3mg and 35 minutes for 1mg compared to placebo for the primary efficacy analysis. HY10275 also met secondary efficacy endpoints including latency to persistent sleep.
HY10275 is a proprietary compound discovered and developed by Hypnion using the SCORE-2004 technology.
“The pharmacodymamic and pharmacokinetic profile of the drug coupled with its unique mechanism of action offers strong promise as a highly differentiated therapeutic. HY10275 could represent a major improvement in the treatment of insomnia as a safe, non-scheduled and well tolerated medication with superior sleep maintenance efficacy and comparable sleep onset efficacy to currently used medications,” said John Dee, president and CEO of Hypnion.